AZD2281, also known as Olaparib, is a poly(ADP-ribose) polymerase 1 (PARP1) inhibitor and an anti-cancer drug being tested in patients with mutations in the genes BRCA1 or BRCA2.
Eribulin is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin suppresses centromere dynamics at concentrations that arrest mitosis.